Is Crinetics Pharmaceuticals Stock a Buy? [Yahoo! Finance]
Crinetics Pharmaceuticals, Inc. (CRNX)
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm
Check Earnings Report
Company Research
Source: Yahoo! Finance
At a $290,000 annual list price, peak sales projections range from $800 million to $1.5 billion, though reaching even 50% market penetration could take years. The stock surged 28% on approval news to $45.91, but commercial execution risks and payer pushback on pricing could derail the revenue ramp Wall Street expects. 10 stocks we like better than Crinetics Pharmaceuticals › Crinetics Pharmaceuticals (NASDAQ: CRNX) faces the ultimate biotech paradox: Its newly approved drug Palsonify could either justify the stock's $4.3 billion valuation or expose it as dangerously overpriced. The U.S. Food and Drug Administration (FDA) approval on Sept. 25 transforms this clinical-stage company into a commercial powerhouse with the first once-daily oral treatment for acromegaly. Wall Street's thinking big. The stock surged 28% on the news. But with only 11,000 diagnosed patients in America and a lofty $290,000 annual price tag, can this rare disease drug actually deliver the returns investo
Show less
Read more
Impact Snapshot
Event Time:
CRNX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRNX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRNX alerts
High impacting Crinetics Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CRNX
News
- Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing TumorsGlobeNewswire
- Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid SyndromeGlobeNewswire
- Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Crinetics Pharmaceuticals (CRNX): Valuation in Focus After FDA Approval and Positive PALSONIFY Launch Momentum [Yahoo! Finance]Yahoo! Finance
- Why Crinetics Pharmaceuticals Stock Was Sliding on Friday [Yahoo! Finance]Yahoo! Finance
CRNX
Earnings
- 11/6/25 - Miss
CRNX
Sec Filings
- 12/3/25 - Form 4
- 12/1/25 - Form 144
- 11/12/25 - Form SCHEDULE
- CRNX's page on the SEC website